T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
EQT Corp
EQT
$33.6B
| $2.08B | 0.45% |
35,698,990
+5,541,347
| +18% | +$318M |
|
52
Bausch Health
BHC
$2.33B
| $2.08B | 0.45% |
16,455,707
+2,398,880
| +17% | +$306M |
|
53
AutoZone
AZO
$50.3B
| $2.03B | 0.44% |
3,789,892
+56,172
| +2% | +$29.7M |
|
54
Roper Technologies
ROP
$39.8B
| $2.01B | 0.44% |
13,788,721
+212,191
| +2% | +$29.6M |
|
|
FISV
55
Fiserv Inc
FISV
$27.9B
| $2B | 0.43% |
66,214,226
+109,784
| +0.2% | +$3.25M |
|
56
Salesforce
CRM
$163B
| $1.96B | 0.42% |
33,727,192
+1,448,773
| +4% | +$78.3M |
|
|
CXO
57
DELISTED
CONCHO RESOURCES INC.
CXO
| $1.81B | 0.39% |
12,524,872
+571,841
| +5% | +$75.9M |
|
|
RHT
58
DELISTED
Red Hat Inc
RHT
| $1.81B | 0.39% |
32,711,223
+3,217,359
| +11% | +$164M |
|
59
Agilent Technologies
A
$42.2B
| $1.79B | 0.39% |
43,648,360
+5,493,305
| +14% | +$221M |
|
|
TFCFA
60
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $1.77B | 0.38% |
50,247,734
+6,366,332
| +15% | +$217M |
|
|
61
Intuitive Surgical
ISRG
$141B
| $1.76B | 0.38% |
38,388,888
+18,500,328
| +93% | +$816M |
|
62
CarMax
KMX
$8.28B
| $1.71B | 0.37% |
32,967,412
-875,044
| -3% | -$39.7M |
|
63
SLB Ltd
SLB
$79.5B
| $1.71B | 0.37% |
14,498,042
-1,522,815
| -10% | -$157M |
|
|
64
US Bancorp
USB
$99.7B
| $1.63B | 0.35% |
37,675,420
-16,431,249
| -30% | -$686M |
|
65
Philip Morris
PM
$288B
| $1.6B | 0.35% |
19,006,962
+3,131,275
| +20% | +$270M |
|
66
Walt Disney
DIS
$180B
| $1.6B | 0.35% |
18,634,301
+1,137,826
| +7% | +$92.9M |
|
67
International Paper
IP
$22.1B
| $1.58B | 0.34% |
33,707,854
+1,402,619
| +4% | +$61.5M |
|
68
Honeywell
HON
$75.1B
| $1.57B | 0.34% |
18,830,251
-346,099
| -2% | -$28.9M |
|
69
CVS Health
CVS
$120B
| $1.54B | 0.33% |
20,428,135
+2,514,316
| +14% | +$190M |
|
|
70
Procter & Gamble
PG
$336B
| $1.53B | 0.33% |
19,433,942
-17,355,253
| -47% | -$1.4B |
|
71
Home Depot
HD
$355B
| $1.51B | 0.33% |
18,671,418
-894,596
| -5% | -$70.6M |
|
|
RDS.A
72
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $1.5B | 0.32% |
19,494,173
+3,307,888
| +20% | +$242M |
|
73
PG&E
PCG
$37.6B
| $1.49B | 0.32% |
30,964,371
+348,340
| +1% | +$15.8M |
|
74
PNC Financial Services
PNC
$101B
| $1.45B | 0.31% |
16,294,317
+973,209
| +6% | +$83.1M |
|
75
Texas Instruments
TXN
$259B
| $1.45B | 0.31% |
30,325,210
+96,130
| +0.3% | +$4.49M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.